NO20110050L - 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander - Google Patents

3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander

Info

Publication number
NO20110050L
NO20110050L NO20110050A NO20110050A NO20110050L NO 20110050 L NO20110050 L NO 20110050L NO 20110050 A NO20110050 A NO 20110050A NO 20110050 A NO20110050 A NO 20110050A NO 20110050 L NO20110050 L NO 20110050L
Authority
NO
Norway
Prior art keywords
dione
chemokine receptor
receptor ligands
cxc chemokine
cyclobutene
Prior art date
Application number
NO20110050A
Other languages
English (en)
Inventor
John J Baldwin
Arthur G Taveras
Jianping Chao
Cynthia J Aki
Richard W Bond
Michael Dwyer
J Robert Merritt
Laura L Rokosz
Bernd Kaiser
Ge Li
Kingsley H Nelson
Johan A Ferreira
Younong Yu
Jianhua Chao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20110050L publication Critical patent/NO20110050L/no
Application filed by Schering Corp filed Critical Schering Corp

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
NO20110050A 2001-04-16 2011-01-12 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander NO20110050L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28402601P 2001-04-16 2001-04-16
PCT/US2002/012681 WO2002083624A1 (en) 2001-04-16 2002-04-15 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Publications (1)

Publication Number Publication Date
NO20110050L true NO20110050L (no) 2003-12-08

Family

ID=23088576

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20034612A NO330790B1 (no) 2001-04-16 2003-10-15 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
NO20110050A NO20110050L (no) 2001-04-16 2011-01-12 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20034612A NO330790B1 (no) 2001-04-16 2003-10-15 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer

Country Status (31)

Country Link
EP (2) EP1818325B1 (no)
JP (3) JP4499993B2 (no)
KR (2) KR20100008794A (no)
CN (2) CN1289471C (no)
AR (1) AR035825A1 (no)
AT (2) ATE365154T1 (no)
AU (3) AU2002311841B2 (no)
BR (1) BRPI0208957B8 (no)
CA (1) CA2444031C (no)
CY (2) CY1109908T1 (no)
CZ (1) CZ20032831A3 (no)
DE (2) DE60220778T2 (no)
DK (2) DK1818325T3 (no)
EC (1) ECSP034809A (no)
ES (2) ES2340207T3 (no)
HK (2) HK1057538A1 (no)
HU (1) HUP0401783A3 (no)
IL (3) IL158262A0 (no)
MX (1) MXPA03009441A (no)
MY (2) MY138202A (no)
NO (2) NO330790B1 (no)
NZ (3) NZ529551A (no)
PE (1) PE20021084A1 (no)
PL (2) PL207255B1 (no)
PT (2) PT1818325E (no)
RU (1) RU2344123C9 (no)
SI (2) SI1818325T1 (no)
SK (1) SK287598B6 (no)
TW (2) TW200736196A (no)
WO (1) WO2002083624A1 (no)
ZA (1) ZA200307905B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CA2462862A1 (en) 2001-10-12 2003-04-17 Schering Corporation 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
MXPA04009127A (es) 2002-03-18 2005-01-25 Schering Corp Tratamiento de enfermedades mediadas por quimiocinas.
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
PE20040570A1 (es) 2002-10-09 2004-08-30 Pharmacopeia Drug Discovery Tiadiazoldioxidos y tiadiazoloxidos como ligandos del receptor de cxc- y cc-quimiocina
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP2258365B1 (en) * 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
ES2325077T3 (es) 2003-04-03 2009-08-25 Merck Patent Gmbh Derivados de 1-(fenilamida)-2-(4-(3-oxo-morfolin-4-il)-fenilamida) del acido pirrolidin-1,2-dicarboxilico y compuestos emparentados como inhibidores del factor de la coagulacion xa, para el tratamiento de las enfermedades tromboembolicas.
EP1615903B1 (en) * 2003-04-18 2010-02-10 Schering Corporation Synthesis of 2-hydroxy-n,n-dimethyl-3- ¬¬ 2-¬ 1(r)-(5-methyl-2-furanyl)propyl amino -3,4-dioxo-1-cyclobuten- 1-yl amino benzamide
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0320983D0 (en) * 2003-09-08 2003-10-08 Biofocus Plc Compound libraries
PT1664007E (pt) * 2003-09-23 2010-02-15 Fermion Oy Preparação de quetiapina
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
MXPA06007076A (es) 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
MXPA06007205A (es) 2003-12-22 2006-08-31 Schering Corp Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimiocina.
MXPA06008599A (es) * 2004-01-30 2006-08-28 Schering Corp Polimorfos cristalinos de un ligando receptor de cxc-quimiocina.
WO2005085197A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
CN101039652A (zh) * 2004-08-16 2007-09-19 宝洁公司 2－(氨基或取代的氨基)－5,6－取代的苯酚化合物，包含该化合物的染料组合物以及它们的应用
EP1634573A1 (en) * 2004-08-16 2006-03-15 The Procter and Gamble Company 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
ES2327840T3 (es) 2004-12-23 2009-11-04 Gpc Biotech Ag Derivados de acido escuarico con actividad antiproliferativa.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CN101253165A (zh) * 2005-06-29 2008-08-27 先灵公司 作为cxc－化学活素受体配体的二取代的二唑
MX2008000367A (es) * 2005-06-29 2008-03-07 Schering Corp Oxidiazolopirazinas y tiadiazolopirazinas 5,6-di-sustituidas como ligandos de receptor de quimiocina en la que dos cisternas son separadas por un solo aminoacido.
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
LT1951663T (lt) * 2005-11-24 2016-11-10 Dompé Farmaceutici S.P.A. (r)-arilalkilamino dariniai ir juos turinčios farmacinės kompozicijos
CA2647592C (en) * 2006-05-26 2014-01-28 Abbott Laboratories Inhibitors of polo-like kinases
CN101500544B (zh) * 2006-06-12 2012-08-08 先灵公司 Cxcr2或cxcr1与cxcr2两者的选择性拮抗剂的药物制剂和组合物及其用于治疗炎性疾病的使用方法
TW200813033A (en) * 2006-07-07 2008-03-16 Schering Corp 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor ligands
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
EP2155670B1 (en) * 2007-06-06 2012-04-18 Novartis AG Anti -inflammatory substituted cyclobutenedione compounds
US8519168B2 (en) * 2007-07-03 2013-08-27 Merck Sharp & Dohme Corp. Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CN102123988B (zh) * 2008-06-24 2013-08-14 顶标公司 作为烟酰胺抑制剂的方酸衍生物
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) * 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
SG10202009963PA (en) 2011-01-07 2020-11-27 Allergan Inc Melanin modification compositions and methods of use
CN103842330B (zh) 2011-09-02 2016-10-19 诺华股份有限公司 抗炎的取代的环丁烯二酮化合物的胆碱盐
FR2981934B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) * 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103242210B (zh) * 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN104334545A (zh) 2012-03-16 2015-02-04 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103382192A (zh) * 2012-05-04 2013-11-06 同创医药(苏州)有限公司 N-单取代哌嗪衍生物的制备
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
AR103264A1 (es) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
CN111225900A (zh) * 2017-08-14 2020-06-02 阿勒根公司 3,4-二取代的3-环丁烯-1,2-二酮及其用途
WO2019067332A1 (en) 2017-09-27 2019-04-04 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
AU2019205786B2 (en) 2018-01-08 2023-12-14 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
EP3852879A1 (en) 2018-09-21 2021-07-28 Pfizer Inc. N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
CN110041309B (zh) * 2019-04-04 2022-01-28 广东工业大学 一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用
WO2021071812A1 (en) * 2019-10-07 2021-04-15 D.E Shaw Research, Llc Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
KR102710925B1 (ko) * 2021-06-01 2024-09-27 부산대학교 산학협력단 신규 스퀘어아마이드 유도체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692915A (ja) * 1992-07-28 1994-04-05 Sumitomo Metal Ind Ltd １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
GB9312210D0 (en) * 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
AU686896B2 (en) * 1994-11-16 1998-02-12 American Home Products Corporation Diaminocyclobutene-3,4-diones
EP0915651A4 (en) * 1996-06-27 2001-10-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) * 1997-01-30 1998-08-25 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6211220B1 (en) * 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
JP2002532457A (ja) * 1998-12-14 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション Ｖｌａ−４により仲介される白血球接着を阻害する３，４−ジアミノ−３−シクロブテン−１，２−ジオン誘導体
EE200100317A (et) * 1998-12-16 2002-08-15 Bayer Aktiengesellschaft Uued bifenüül- ja bifenüülanaloogsed ühendid kui integriini antagonistid
US6518283B1 (en) * 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AR033803A1 (es) * 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
CN1454204A (zh) * 2000-05-30 2003-11-05 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
AR032398A1 (es) * 2001-01-16 2003-11-05 Smithkline Beecham Corp Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion
US20040110954A1 (en) * 2001-03-30 2004-06-10 Palovich Michael R. Methods of synthesizing phenol-contining compounds
MXPA04009127A (es) * 2002-03-18 2005-01-25 Schering Corp Tratamiento de enfermedades mediadas por quimiocinas.

Also Published As

Publication number Publication date
NZ560453A (en) 2009-03-31
MXPA03009441A (es) 2004-02-12
DE60235507D1 (de) 2010-04-08
DK1818325T3 (da) 2010-05-31
IL158262A (en) 2012-05-31
CA2444031C (en) 2012-02-21
JP5294418B2 (ja) 2013-09-18
SI1818325T1 (sl) 2010-06-30
JP4499993B2 (ja) 2010-07-14
CN1516687A (zh) 2004-07-28
HK1107818A1 (en) 2008-04-18
EP1381590B1 (en) 2007-06-20
CA2444031A1 (en) 2002-10-24
KR100952531B1 (ko) 2010-04-12
IL158262A0 (en) 2004-05-12
AU2006203679A1 (en) 2006-09-14
BR0208957A (pt) 2004-06-22
AU2010212484B2 (en) 2012-04-12
KR20100008794A (ko) 2010-01-26
ES2287284T3 (es) 2007-12-16
PL367129A1 (en) 2005-02-21
SK287598B6 (sk) 2011-03-04
HK1057538A1 (en) 2004-04-08
ATE365154T1 (de) 2007-07-15
CY1109908T1 (el) 2014-09-10
PL208928B1 (pl) 2011-06-30
PT1818325E (pt) 2010-05-12
NO20034612L (no) 2003-12-08
ATE458715T1 (de) 2010-03-15
RU2003133448A (ru) 2005-06-10
ECSP034809A (es) 2004-02-26
SK12882003A3 (sk) 2004-06-08
IL201754A0 (en) 2010-06-16
EP1818325B1 (en) 2010-02-24
DE60220778T2 (de) 2008-03-06
CN1990457A (zh) 2007-07-04
BRPI0208957B1 (pt) 2018-10-09
JP2009179641A (ja) 2009-08-13
AU2010212484A1 (en) 2010-09-09
EP1818325A2 (en) 2007-08-15
TW200736196A (en) 2007-10-01
MY149050A (en) 2013-07-15
PT1381590E (pt) 2007-08-06
SI1381590T1 (sl) 2007-10-31
EP1381590A1 (en) 2004-01-21
ES2340207T3 (es) 2010-05-31
HUP0401783A2 (hu) 2005-01-28
BRPI0208957B8 (pt) 2021-05-25
CY1109989T1 (el) 2014-09-10
WO2002083624A1 (en) 2002-10-24
NZ529551A (en) 2006-02-24
PE20021084A1 (es) 2002-12-20
AR035825A1 (es) 2004-07-14
CN1289471C (zh) 2006-12-13
AU2002311841B2 (en) 2006-09-14
KR20030092074A (ko) 2003-12-03
MY138202A (en) 2009-05-29
JP2004532846A (ja) 2004-10-28
ZA200307905B (en) 2005-03-30
NZ543869A (en) 2007-09-28
DK1381590T3 (da) 2007-10-22
EP1818325A3 (en) 2008-02-13
RU2344123C9 (ru) 2009-05-20
JP2010053151A (ja) 2010-03-11
NO20034612D0 (no) 2003-10-15
RU2344123C2 (ru) 2009-01-20
DE60220778D1 (en) 2007-08-02
PL207255B1 (pl) 2010-11-30
CZ20032831A3 (cs) 2004-03-17
NO330790B1 (no) 2011-07-18
TWI316930B (en) 2009-11-11
HUP0401783A3 (en) 2005-06-28

Similar Documents

Publication Publication Date Title
NO20110050L (no) 3,4-disubstituerte syklobuten-1,2-dioner som CXC-kjemokinreseptorligander
NO20033424D0 (no) 3,4-disubstituerte syklobuten-1,2-dioner som CXC- kemokinreseptorantagonister
ITTO20010940A0 (it) ,,sedia,,
NO20042373L (no) Nye 1,2,4-tiadiazoliumderivater som melanokortinreseptormodulatorer
DE60225341D1 (de) Neue 1,2,4-triazolverbindung
NO20041560L (no) 1,6-nafthyridinderivater som antidiabetiske midler
NL1021752A1 (nl) Katalysators.
DK1414440T3 (da) N-phenylpyrrolguanidinderivater som melanocortinreceptorligander
DE60131971D1 (de) 1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN
AU2003207460A1 (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
DK1381596T3 (da) Thiazolylsubstituerede carbocykliske 1,3-dioner som pesticider
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
BR0204153B1 (pt) transmissão.
NO20044413L (no) 1,2-Dihydropyrazol-3-oner som cytokinmediatorer
ITTO20020747A1 (it) Composizione.
ITTO20020745A1 (it) Composizione.
ATE470655T1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
SE0301847D0 (sv) Novel 3,3-Diphenylpropylamines
ES1048499Y (es) Persiana compacta.
IT1317620B1 (it) Struttura di profilato, particolarmente per la realizzazione diserramenti tagliafuoco.
DE60224192D1 (de) Antihaemorrhagische, betain-enthaltende zusammenseuzungen
DOP2001000275A (es) Inhibidores de metaloproteinasa del tipo pirmidin-2,4,6-triona.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

FC2A Withdrawal, rejection or dismissal of laid open patent application